SCHEMBL15224255

SCHEMBL15224255

NC(=O)CC(=O)N1CCN(c2ccccc2F)CC1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.69
MEN1 O00255 4/20 0.69
TSHR P16473 3/20 0.69
MAPT P10636 3/20 0.69
LMNA P02545 3/20 0.69
SMN1; SMN2 Q16637 3/20 0.60
NPC1 O15118 3/20 0.59
RAB9A P51151 3/20 0.59
ALDH1A1 P00352 3/20 0.59
POLB P06746 3/20 0.59
KDM4E B2RXH2 1/20 0.58
ALOX15 P16050 1/20 0.58
CYP1A2 P05177 1/20 0.58
CYP2C9 P11712 1/20 0.58
CYP2C19 P33261 1/20 0.58
TDP1 Q9NUW8 1/20 0.56
MAPK1 P28482 1/20 0.56
NPSR1 Q6W5P4 1/20 0.56
HSD17B10 Q99714 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15224268 0.87 KMT2A (0.76) KMT2AMEN1TSHRMAPTLMNA
SCHEMBL15224256 0.85 KMT2A (0.83) KMT2AMEN1TSHRMAPTLMNA
SCHEMBL15224152 0.82 AR (0.60) KMT2ATSHRMAPTALDH1A1KDM4E
SCHEMBL14224489 0.82 KMT2A (0.73) KMT2AMEN1TSHRMAPTLMNA
SCHEMBL15224269 0.81 KMT2A (0.86) KMT2AMEN1TSHRMAPTLMNA
SCHEMBL27918174 0.79 SMN1; SMN2 (0.73) KMT2AMEN1TSHRMAPTLMNA
SCHEMBL27597072 0.79 ALDH1A1 (0.64) KMT2AMEN1TSHRMAPTLMNA
SCHEMBL31406852 0.78 KMT2A (0.68) KMT2AMEN1TSHRMAPTLMNA
SCHEMBL5234913 0.78 KDM4E (0.73) KMT2AMEN1TSHRMAPTLMNA
SCHEMBL2824053 0.77 KMT2A (1.00) KMT2AMEN1TSHRMAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8822452-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2014-09-02 US disclosed
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2013-11-14 US disclosed
US-8524894-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2013-09-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 KMT2A 3868/4885MEN1 827/4885TSHR 3844/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.